HSR22-129: The Cost of Treatment of HR+/HER2- Early Breast Cancer and Implications for the Cost-Effectiveness of Multigene Assays in the US
- Resource Type
- Source
- Journal of the National Comprehensive Cancer Network. 20:HSR22-129
- Subject
Oncology - Language
- ISSN
- 1540-1413
1540-1405